Paper39360565
Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab.
Sharma P and 3 others. CPT Pharmacometrics Syst Pharmacol, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab. Papers, record 39360565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39360565
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Receptor, Interferon alpha-beta | Major topic |
| Models, Biological | Major topic |
| Transcriptome | Major topic |
| Humans | |
| Tissue Distribution | |
| Lupus Erythematosus, Systemic | |
| Antibodies, Monoclonal |
Source PubMed
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29644082 | Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. | Lupus Sci Med | 2018 | https://conductscience.org/library/papers/29644082 | PubMed |
| 2 | 25613900 | Proteomics. Tissue-based map of the human proteome. | Science | 2015 | https://conductscience.org/library/papers/25613900 | PubMed |
| 3 | 25601866 | Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. | Front Immunol | 2014 | https://conductscience.org/library/papers/25601866 | PubMed |
| 4 | 38229377 | Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. | Lancet Rheumatol | 2019 | https://conductscience.org/library/papers/38229377 | PubMed |
| 5 | 19199378 | The Simcyp population-based ADME simulator. | Expert Opin Drug Metab Toxicol | 2009 | https://conductscience.org/library/papers/19199378 | PubMed |
| 6 | 33629110 | Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus. | Rheumatology (Oxford) | 2021 | https://conductscience.org/library/papers/33629110 | PubMed |
| 7 | 28956281 | Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus. | Patient | 2018 | https://conductscience.org/library/papers/28956281 | PubMed |
| 8 | 27909650 | PBPK modeling and simulation in drug research and development. | Acta Pharm Sin B | 2016 | https://conductscience.org/library/papers/27909650 | PubMed |
| 9 | 28392453 | Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins. | J Pharm Sci | 2017 | https://conductscience.org/library/papers/28392453 | PubMed |
| 10 | 28130918 | Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. | Arthritis Rheumatol | 2017 | https://conductscience.org/library/papers/28130918 | PubMed |
| 11 | 35352835 | Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus. | J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/35352835 | PubMed |
| 12 | 32141953 | Treatment of cutaneous lupus erythematosus: current approaches and future strategies. | Curr Opin Rheumatol | 2020 | https://conductscience.org/library/papers/32141953 | PubMed |
| 13 | 22550964 | Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. | Clin Pharmacokinet | 2012 | https://conductscience.org/library/papers/22550964 | PubMed |
| 14 | 36063748 | Correlation between IFNAR1 expression in peripheral blood T lymphocytes and inflammatory cytokines, tumor-infiltrating lymphocytes, and chemosensitivity in patients with colorectal cancer. | Cytokine | 2022 | https://conductscience.org/library/papers/36063748 | PubMed |
| 15 | 21881594 | Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. | Genes Immun | 2012 | https://conductscience.org/library/papers/21881594 | PubMed |
| 16 | 14669296 | Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma. | Cancer | 2003 | https://conductscience.org/library/papers/14669296 | PubMed |
| 17 | 25265476 | Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. | PLoS One | 2014 | https://conductscience.org/library/papers/25265476 | PubMed |
| 18 | 29644080 | Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. | Lupus Sci Med | 2018 | https://conductscience.org/library/papers/29644080 | PubMed |
| 19 | 26408308 | A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins. | AAPS J | 2016 | https://conductscience.org/library/papers/26408308 | PubMed |
| 20 | 31236450 | Preference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLE. | J Patient Exp | 2019 | https://conductscience.org/library/papers/31236450 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42382290 | Integrating in vitro aerosol characterization and cross-species PBPK modeling to predict human lung exposure of inhaled therapeutic proteins. | Int J Pharm X | 2026 | https://conductscience.org/library/papers/42382290 | PubMed |
| 42292405 | The landscape of cellular immune alteration in systemic lupus erythematosus. | Front Immunol | 2026 | https://conductscience.org/library/papers/42292405 | PubMed |
| 41459511 | Conceptual quantitative systems pharmacology framework for supporting clinical trial design in organ-specific autoimmune and rare diseases. | Front Immunol | 2025 | https://conductscience.org/library/papers/41459511 | PubMed |
| 39771538 | The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39771538 | PubMed |
| 39360565 | Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab. | CPT Pharmacometrics Syst Pharmacol | 2025 | https://conductscience.org/library/papers/39360565 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IFNAR1 | 3454 | PubTator's text mining | https://conductscience.org/library/genes/3454 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39360565
GET https://conductscience.org/api/papers/v1/39360565/references?page=2